JILIN, China, Dec 05, 2005 /Xinhua-PRNewswire via COMTEX/ -- Global Pharmatech, Inc. (OTC PK: GBLP) announced today that its majority-owned subsidiary, Jilin BCT Pharmaceutical Co., Ltd., recently received three new drug approvals from the State Food and Drug Administration of the People's Republic of China. The approvals allow for its botanical drugs products, Jin Lian Hua Capsule, Gong Yan Kang Granules and Wei Kang Ling Capsule to be marketed and sold in China. Global Pharmatech, develops, manufactures and markets proprietary drugs and nutritional supplements that are based on modernized Chinese medicine and bio-pharmacy. Through its subsidiaries, Global Pharmatech combines R&D of botanical drug products, manufacturing, and sales and marketing for the Over-the-Counter (OTC) and prescription drug markets.
Jin Lian Hua Capsule is a modernized botanical drug product. Development of this product was based on previous clinical experiences of traditional Chinese medicine. This product is for the treatment of pharyngitis, tonsillitis, and other types of various upper airway inflammatory diseases.
The drug substances of Gong Yan Kang Granule are extracted from several botanical materials. It is used for the treatment of chronic hysteritis, adnexitis and other gynecologic diseases.
Wei Kang Ling Capsule was developed based on the principles of traditional Chinese medicine. The indications of this product are chronic gastritis, gastric and intestinal ulcers.
Dr. Sun Xiaobo, President and CEO of Global Pharmatech, commented, ''We have high expectations for these newly-developed botanical drug products. The features of these products have high efficacy and low side-effects. We are currently starting to design our marketing strategy for the promotion of these three products. We will launch these products in the first quarter of 2006. Based on current projections, we estimate potential revenues from sales of these three products may exceed $1 million in next year. .
About Global Pharmatech
Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine using modern facilities and advanced R&D technologies. The company offers a full range of ''start to finish'' biotech services, from research and testing to manufacture and sale of liquid and solid dose products employing unique proprietary extraction methods, and also licenses patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution in China, Malaysia, Singapore and Indonesia.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995.
This news release contains forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to successfully develop and commercialize products, competitive products in our key markets, changes in consumer demand for our products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.